TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Why TG Therapeutics (TGTX) Stock Crashed 40% Today
November 30, 2021 8:54 AM ESTTG Therapeutics (NASDAQ: TGTX) stock price is down nearly 40% today after the company announced the U.S. Food and Drug Administration (FDA) plans to hold a meeting of the Oncologic Drugs Advisory Committee (ODAC).
The Committee will discuss and review pending TGTXs application for the combination of ublituximab and UKONIQ (umbralisib) (known as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma... More
TG Therapeutics (TGTX) Issues Regulatory Update
November 30, 2021 7:33 AM ESTTG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ® (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, We... More
